MaaT Pharma · EURONEXT:MAAT
MaaT Pharma — Investor Day (June 2022)
93 slides from MaaT Pharma's investor day presentation, Jun 7, 2022
Slide 1: Investor R&D Day
Investor R&D DAY June 7th, 2022
Slide 2: Introduction & Opening remarks
Introduction & Opening remarks Hervé Affagard CEO R&D Day June 7, 2022
Slide 3: Disclaimer
Disclaimer No representation, warranty or undertaking, express or implied, is made as to the accuracy, This document has been prepared by MaaT Pharma (the "Company") and is for information and background completeness or appropriateness of the information and opinions contained in this document. purp
Slide 4: Today's agenda
Today’s agenda The Microbiome Revolution Dr. Joël Doré- Research Director, INRAE and Scientific Advisor at MaaT Pharma Driving Value in the Microbiome Space Hervé Affagard - CEO and co-founder The Microbiome: a new frontier in hematological Pr. Ernst Holler, M.D –Senior Professor on Clinical and Exp
Slide 5: Key messages for today
Key messages for today • Based on the tremendous progress of microbiome science in the past 15 years, Unique strategy the microbiome global industry is now becoming more mature positioning in a growing microbiome • MaaT Pharma is pioneering Microbiome Ecosystem Therapies, offering a differentiated a
Slide 6: The microbiome revolution
The microbiome revolution Dr. Joël Doré INRAE Research Director, Scientific Director of Métagénopolis, Scientific Advisor R&D Day June 7, 2022
Slide 7: The human is microbial: ecosystem and symbiosis
The human is microbial: ecosystem and symbiosis ~50 000 000 000 000 bacteria: as many as human cells in our body > 600 000 microbial genes*: 25 X the number of human genes < 4% human genes our microbiomes are “autochthonous” and specific to ecological niches they occupy Microbiome science change
Slide 8: The microbiota provides key protective functions
The microbiota provides key protective functions microbiota Human genes and The microbiota acts as: their functions Host-microbes SYMBIOSIS Endocrine- Immuno- Antimicrobial Neuro- Microbial genes and their metabolic inflammatory “barrier” vegetative regulator regulator regulator functions R&D Day Ju
Slide 9: Host-microbes symbiosis: A symbiotic relationship that starts at birth
Host-microbes symbiosis: A symbiotic relationship that starts at birth Maintenance of symbiosis Immune Health and well-being maturation ‘UNIQUE’ SYMBIOSIS: microbiota & recognized as a Disruption of ecology : Microbiota component • Loss of ‘barrier’ function development of ‘SELF’ • Risk of infecti
Slide 10: Circular causalities and dysbiosis
25% of the worldwide population is affected by an atrophied microbiome and dysbiosis1 Conditions with uncontrolled rising incidence Oxidative stress Low richness microbiota • Autism Spectrum Disorders • Major Depressive Disorders At least 4 actionable levers CNS • Multiple sclerosis circular causali
Slide 11: Urgent paradigm shift: holistic approach to health and microbiome
Urgent paradigm shift: Adopting a holistic approach to health, taking into account the microbiome/host symbiosis Key features of a health-associated microbiota • High richness • Robustness: resistance and resilience • Shared core microbiome • Symbionts driving immune-homeostasis • Influenced by nume
Slide 12: Microbiota richness is a major health stratifier
Microbiota richness is a major health stratifier… Bimodal distribution of population (FR, DK) based on microbiota gene-count low gene-count to high gene-count Low microbiota richness, LGC: low gene count (LGC) ≈ 15 % in non obese ≈ 40% in overweight ≈ 75% in morbid obesity A low gene count is associ
Slide 13: In cancer therapy, a low gene count is associated with worse outcomes
… specifically in cancer therapy, a low gene count is associated with… … lesser progression-free … lesser overall survival in … higher mortality by survival with immunotherapy patients receiving allogenic acute Graft versus Host in melanoma and in lung stem cell transplants Disease cancer -30% morta
Slide 14: Modulating the microbiome opens new horizons
Modulating the microbiome opens new horizons towards personalized holistic approaches 1 Symbiosis: Human tissues and organs interact with the microbiota, with mutual benefits 2 Alteration of symbiosis comes with loss of protective functions The gut microbiota is a relevant target for the maintenance
Slide 15: Thank you for your attention
Thank you for your attention MetagenoPolis Alexandre Cavezza Nicolas Lapaque, S. Dusko Ehrlich Joël Doré, Joël Doré Hervé Blottière, Hervé Blottière Catherine Juste, Mathieu Almeida Christel Béra-Maillet, Christian Morabito Jean-Marc Lelièvre, Hugo Roume Alexandre Jamet, Florence Haimet Maarten van
Slide 16: Driving value in the microbiome space
Driving value in the microbiome space Hervé Affagard CEO R&D Day June 7, 2022
Slide 17: Pioneering innovative microbiome therapy for patients fighting cancer
Driving Pioneering innovative microbiome therapy for the benefit of value millions of patients fighting cancer Leveraging the complexity of Manufacturing the microbiome versatility Pioneering a full ecosystem cGMP manufacturing scalability approach to restore for both native and co-fermented host/mi
Slide 18: Balanced pipeline focused on oncology Microbiome Ecosystem Therapies
Driving value Balanced pipeline focused on oncology Microbiome Ecosystem cGMP Therapies (MET) Platform Native Co-fermented MaaT013 MaaT033 MaaT03X Indication-specific designed High diversity ecosystem (from clinical data) Full ecosystem Innovative ecosystem co- ButycoreTM (anti-inflammator
Slide 19: Delivering on our objectives
Driving value Delivering on our objectives Clinical program Milestones announced at IPO Status (Nov 2021) MaaT013 (pooled enema) Onco-hematology Launch of the first Phase 3 trial in FDA & EMA Orphan Drug Designation oncology in the world MaaT033 (pooled capsule) Completion of Phase 1b trial and Post
Slide 20: Looking ahead: addressing growing market opportunities
Driving value Looking ahead: addressing growing market opportunities with severe medical need MaaT03X MaaT03X MaaT033 >200,000 patients1 ~ 22,000 patients1 MaaT013 ~ 2,000 patients1 Long-term 3rd line Prevention of Solid Tumors in complications combination with Expansion SR GI 10x >10x TAM aGvHD of
Slide 21: Microbiome: a new frontier in hematological cancer treatment?
Hemato- Oncology Microbiome: a new frontier in hematological cancer treatment? Pr. Ernst Holler Senior Professor on Clinical and Experimental Allogeneic SCT, Dept of Internal Medicine 3, University Hospital Center Regensburg, Germany R&D Day June 7, 2022
Slide 22: The Concept
The Concept Ménage à trois: Microbiome (metabolites of commensals) Immune cells Tumor cells Holler et al, Gastroenterologe und Best Practice Onkologie 2019 R&D Day June 7, 2022 22
Slide 23: The Principles of allogeneic Stem Cell Transplantation
The Principles of allogeneic Stem Cell Transplantation (SCT) Conditioning HLA-Antigen -reduction of tumor cells matched donor -Prevention of rejection (sibling/unrelated) (=Host-vs-Graft) Allogeneic stem cells and T lymphocytes Aplasia -> Hematopoietic reconstitution <- Immunosuppressive and anti-in
Slide 24: Graft-versus-Host and Graft-versus-Leukemia reactions
Graft-versus Host (GvH) and Graft-versus-Leukemia (GvL) reactions by donor cells GvL The clinical problem: • Only 50 – 70% of patients can be cured • Treatment related mortality by GvHD (20-30%) and GvH morbidity skin • Mortality increases to 80% if GvHD is refractory to treatment + GvH Relapse of u
Slide 25: Gut microbiome: an old player in allogeneic HSCT
Gut microbiome: an old player in allogeneic hematopoietic stem cell transplantation (HSCT) Microbiota and complications of stem cell transplantation 1980-2000 D100 survival • Comparable results: after BMT in mice • Rhesus monkeys (van Bekkum 1975) • Dogs (Vriesendorp 1981) 100% • Complete decontamin
Slide 26: Molecular microbiota analysis revealed severe dysbiosis in HSCT
A new era in HSCT : Molecular microbiota analysis revealed severe dysbiosis in HSCT patients Non cultural 16s rRNA analyses allowed detection of >60% new non cultivated species: Dysbiotic “scar” in No leukemia patients Antibiotics “Decontamination” is rarely complete but there is a massive loss of m
Slide 27: Loss of intestinal commensal microbiota affects outcome 1/2
A universal finding: loss of intestinal commensal microbiota affects outcome after HSCT across centers 1/2 (New York, Duke, Hokkaido, Regensburg) Lactose drives enterococcal expansion to promote GvHD Ch Stein-Thoeringer et al, Science 2019 R&D Day June 7, 2022 27
Slide 28: Loss of intestinal commensal microbiota affects outcome 2/2
A universal finding: loss of intestinal commensal microbiota affects outcome after HSCT across centers 2/2 (New York, Duke, Hokkaido, Regensburg) Microbiota as Predictor of Mortality in ASCT a multicenter observational study Peled J et al, NEJM 2020 28 R&D Day June 7, 2022
Slide 29: Causes of dysbiosis (1): Paneth cell damage by GvHD
Causes of dysbiosis (1): Paneth cell damage by GvHD itself No GvHD: GvHD: crypt destruction Corresponding systemic Reg3a serum levels no crypt destruction Blood GvHD GI tract GvHD Levine et al, Blood 2013, Weber et al, PLoSone 2017 Expression of antimicrobial peptides (alpha-Defensins 5 and 6, Reg3a
Slide 30: Causes of dysbiosis (2): broad-spectrum antibiotics
Causes of dysbiosis (2): Early and prolonged use of broad-spectrum antibiotics Initiation of systemic AB Retrospective analysis of 621 patients from 2 centers (MSKCC, Regensburg): Early vs late AB: p=0.001 Early vs no AB: p<0.001 Early ABX: 34% TRM - Early antibiosis was associated with more severe
Slide 31: Loss of protective metabolites after antibiotic treatment
Consequences of antibiotic treatment: Loss of protective metabolites (SCFA like Butyrate and Indoles) and subsequent loss of protective immunoregulation in GvHD tissues Correlation of Butyrate receptors with Broad spectrum iv ABX at biopsy regulatory T cells (p 0.005) No (30) Yes (54) G I b io p s i
Slide 32: Microbiota-derived SCFA improve T cell and CAR-T treatment
And the next association: Microbiota derived SCFA improve antigen-specific T cell and CAR-T cell9 treatment Some proof: Luu M, Riester Z, Baldrich A, et al. Microbial short- chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat Commun. 2021;12(1):4077. T
Slide 33: Conclusion
Conclusion SCFA T regs Microbiota Microbiota restoration? IL22 Indoles The concept of tissue tolerance P Reddy, Blood Perspective Blood 2017; 129 (13) Right balance needed R&D Day June 7, 2022 33
Slide 34: MaaT013, first-in-class Microbiome Ecosystem Therapy in Phase 3 in GvHD
aGvHD MaaT013, first-in-class Microbiome Ecosystem Therapy in Phase 3 in Graft-vs-Host-Disease Dr. Florent Malard Professor of Haematology Emilie Plantamura Head of clinical development R&D Day June 7, 2022
Slide 35: Results from Phase 2 Clinical Trial and Early Access Program
aGvHD Results from Phase 2 Clinical Trial and Early Access Program Pr. Florent Malard Professor of Haematology R&D Day June 7, 2022
Slide 36: An urgent medical need in acute Graft-vs-host Disease
aGvHD An urgent medical need in acute Graft-vs-host-Disease (aGvHD) Intestinal dysbiosis is associated with higher mortality in hemato-oncology Chemotherapy Antibiotics Allogenic Hematopoietic Stem Cell Irradiation, Transplantation (allo-HSCT) Immunosuppressors ~ 22 000 patients/yr1 MaaT013 Steroids
Slide 37: MaaT013 aims to restore interaction between microbiome and immune system
aGvHD MaaT013 aims to restore interaction between the microbiome and the immune system to treat aGvHD MaaT013 High richness and diversity Reset microbial network ButycoreTM Immune homeostasis Restored barrier Integrity restoration (prevention of infection) ↗ Diversity Inhibition of pathogen grow
Slide 38: MaaT013: restore the microbiome to cure acute GI GvHD
aGvHD MaaT013: restore the microbiome to cure acute Gastro-Intestinal graft vs. Host disease. Characteristics Pooled microbiota: a high-richness, high-diversity, full ecosystem, containing ButycoreTM Administration 3 doses (150 mL enema bag) Available Clinical Data HERACLES Phase 2 Clinical Trial,
Slide 39: Two complementary approaches generating data on MaaT013
aGvHD Two complementary approaches generating data on MaaT013 Early Access Program Phase 2 clinical trial - HERACLES (ex « ATU ») • Phase 2 clinical trial HERACLES (NCT03359980) • Authorized par the French regulator (ANSM) • 24 patients, 4 countries • 52 patients, France • Gastro-intestinal aGvHD gr
Slide 40: HERACLES Phase 2 Clinical Trial: promising results
aGvHD Phase 2 HERACLES Phase 2 Clinical Trial (N=24) Promising results in a very severe population (grade III-IV) GI-Response 60% 54% • 2nd line 4% • 96% grade III, 4% grade IV 50% • 100% steroid-resistant (SR) 13% • Gastrointestinal (GI) predominant 40% 38% 8% 30% • Very good safety and tolerabilit
Slide 41: HERACLES: MaaT013 increases Responders' survival
aGvHD Phase 2 HERACLES Phase 2 Clinical Trial MaaT013 increases Responders’ survival Overall Survival Rate Responders vs. Non responders 6 mo 12 mo 44% 44% 20% 13% Days after first MaaT013 dose R&D Day June 7, 2022 42
Slide 42: HERACLES: MaaT013 increases Responders' gut microbiome diversity
aGvHD Phase 2 HERACLES: MaaT013 increases Responders’ gut microbiome diversity Microbiota Diversity *** 0.0006 * 0.0360 ** 5 0.0056 S h a n n o n I n d e x ( O T U le v e l) n.s. 0.2624 n.s. 0.2345 * 0.0426 4 3 n.s. 0.1383 2 1 0 V1 V2 V3 V4 M aaT013 Responders Non-responders MaaT013 R&D Day June 7,
Slide 43: Early Access Program: a promising confirmation
aGvHD EAP Early Access Program (EAP): A promising confirmation in a more diverse population GI-Reponse 80% • 3 doses , 2nd to 7th line (median 4) 70% 67% 60% 58% 8% • 52 patients • 83% steroid-resistant / 17% steroid- 8% dependent 50% 19% • 94% grade III 40% 17% • 100% GI involvement 30% • 77% have
Slide 44: Early Access Program: very promising overall survival results
aGvHD EAP Early Access Program (EAP): Very promising overall survival results at 6 mo and 1 year Overall Survival Rate Overall Survival Rate All patients Responders vs. Non responders 100 6 mo 12 mo 100 6 mo 12 mo Overall survival (%) Overall survival (%) 70% 80 80 59% 60 49% 60 38% 40 40 21% 20 22%
Slide 45: Promising clinical results supporting the launch of pivotal Phase 3
MaaT013 aGvHD Promising clinical results supporting the launch of pivotal Phase 3 • MaaT013 increases Responders’ microbiome diversity. • The clinical response to MaaT013 translates in increased overall survival in both patient populations tested. • Overall safety is good • SAEs were consistent with
Slide 46: Acknowledgments
Acknowledgments Patients, Caretakers and Healthy Donors involved • Michael Loschi, Thomas Cluzeau (CHU Nice) • Ernst Holler (Regensburg) • Faezeh Legrand, Reynier Devillier, Angela Granata, Valerio • Etienne Daguindau (CHU Besancon) Maisano (Institut Paoli Calmettes) • Karin Bilger (CHU Strasbourg)
Slide 47: ARES Study, a pivotal Phase 3 clinical trial in aGvHD
MaaT013 Phase 3 ARES Study, a pivotal Phase 3 clinical trial investigating MaaT013 in aGvHD Emilie Plantamura Head of clinical development R&D Day June 7, 2022
Slide 48: ARES, a pivotal study to treat GI-aGvHD
aGvHD Phase 3 ARES, a pivotal study to treat GI-aGvHD International study incl. 6 to 8 countries with first-time countries working with MaaT013 – up to 50 reference centers Pivotal single arm trial of MaaT013 as 3rd line (steroid- & ruxolitinib-refractory patients) 29 months total duration Up to one
Slide 49: Targeted timelines ARES trial
aGvHD Phase 3 Targeted timelines ARES trial EUROPE : USA: CTA approved in 3 European countries. • FDA requested further information – on clinical hold. Expected to expand to additional EU countries Submitted a request for a “Type A” meeting to the FDA by the end of 2021, with the support of well
Slide 50: ARES, a pivotal Phase 3 trial to treat aGvHD in 3rd line
aGvHD Phase 3 ARES, a pivotal Phase 3 trial to treat aGvHD in 3rd line Patients with SR- GI-aGvHD 10 days - Treatment period Primary follow-up Long-term follow-up Screening EOT (D-14 to D-1) MaaT013 administration Inclusion D28 M12 D1 M6 criteria Refractory or intolerant to ruxolitinib Refractor
Slide 51: ARES Objectives
aGvHD Phase 3 ARES Objectives Primary: Evaluation of treatment response MaaT13 efficacy evaluation assessed by the ORR (CR, VGPR and PR) of GI-aGVHD response at Day 28 Secondary - SAFETY Secondary - EFFICACY Secondary - EXPLORATORY Overall Safety Assessment • ORR for GI and all organs up to • MaaT01
Slide 52: MaaT013 to cure aGvHD
MaaT013 aGvHD MaaT013 to cure aGvHD • MaaT013 is a first-in-class, high-richness, high-diversity full ecosystem microbiome therapy, containing ButycoreTM • MaaT013 aims to restore the microbiome to cure Gastro-Intestinal acute Graft vs. Host disease, a severe complication of allogeneic stem cell tra
Slide 53: MaaT033, oral Microbiome Ecosystem Therapy for liquid tumors
Hemato- Oncology 15 min MaaT033, oral Microbiome Ecosystem Therapy aiming to improve outcomes for patients with liquid tumors Pr. Mohamad Mohty Professor & Head of the Clinical Hematology and Cellular Department - Saint-Antoine Hospital R&D Day June 7, 2022
Slide 54: MaaT033: An optimized oral capsule
Hemato- Oncology MaaT033: An optimized oral capsule to restore and maintain a healthy gut microbiome in patients with severe dysbiosis Characteristics A high-richness and high-diversity full-ecosystem intestinal Microbiome Ecosystem Therapy Administration Oral (a lyophilized capsule) Clinical progra
Slide 55: MaaT033 aims to restore and preserve the gut microbiota
Allo-HSCT MaaT033 aims to restore and preserve the gut microbiota, to avoid allo-HSCT complications (infections & aGvHD) Chemotherapy Allogenic Hematopoietic Stem Cell Antibiotics Transplantation (allo-HSCT) Irradiation, Immunosuppressors Before After MaaT033 Restore & Protect microbial network Pati
Slide 56: MaaT033's mechanism of action
Allo-HSCT MaaT033’s MOA aims to to restore and protect the gut microbiota, to improve allo-HSCT outcome and avoid complications (infections, aGvHD, etc.) MaaT033 High richness and diversity Reset microbial network ButycoreTM Immune homeostasis Restored barrier Integrity restoration (prevention o
Slide 57: Introducing CIMON, the first clinical trial evaluating MaaT033
AML Phase 1b Introducing CIMON, the first clinical trial evaluating MaaT033 … Phase 1 evaluation of MaaT033 in patients with acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome, after intensive chemotherapy Dose-ranging study 6 centers in France, N=21 patients Primary endpoint: safety Key s
Slide 58: A Phase 1b open-label, dose finding study
AML Phase 1b … a Phase 1b open-label, dose finding study Visit 1 Visit 2 Visit 3 Visit 4 Day 0 Inclusion 1 week 1 week 1 week 3 weeks 21 acute myeloid MaaT033 treatment Consolidation or leukemia patients phase other cycle After induction therapy with intensive chemotherapy Cohort 5 (n= 6) Not perfor
Slide 59: MaaT033 displayed a good safety profile in CIMON study
AML Phase 1b MaaT033 displayed a good safety profile in CIMON study 21 patients exposed, 20 completed. 100% drug compliance. 4/4 positive DSMB meetings recommending cohort escalations: • 4 SAEs considered “not related” to study drug by the investigator. • 1 SAE “possibly related” : infectious
Slide 60: Strong, rapid and persistent engraftment in CIMON study
AML Phase 1b MaT033 displayed strong, rapid and persistent engraftment in CIMON study MaaT033 engraftment (mean, SD) (specific to MaaT033 i.e., exclude shared OTUs between 100 MaaT033 and patients at baseline) 80 O T U s (% ) 60 c o h o rt 1 E n g ra ftm e n t, C o h o rt 2 C o h o rt 3 40 C o h o r
Slide 61: CIMON results open an attractive market opportunity
Allo-HSCT CIMON results open an attractive market opportunity: Prevention of complications in patients receiving allo-HSCT and in hematological malignancies overall 100% United States EU 5 Japan c. 7,800 c. 9,600 c. 3,000 primary primary primary procedures procedures procedures CIMON Additional 7%-1
Slide 62: Next step: Randomized clinical trial evaluating MaaT033
MaaT033 Allo-HSCT Next step: Randomized clinical trial evaluating MaaT033 to prevent complications of allo-HSCT • 341 patients in a randomized, double-blind, placebo-controlled study • Evaluate safety and tolerability before and after allo-HSCT • Evaluate engraftment and efficacy of MaaT033 in impro
Slide 63: MaaT033: Promising new treatment for allo-HSCT
Allo-HSCT MaaT033: Promising new treatment for allo-HSCT • MaaT033 is an oral, high-richness, high-diversity microbiome therapy • MaaT033 aims to restore and maintain a healthy microbiome in patients with severe dysbiosis • MaaT033 promotes SCFA including butyrate and other metabolites production to
Slide 64: The microbiome is gaining momentum in cancer immunotherapy
Immuno- Oncology The microbiome is gaining momentum in cancer immunotherapy Pr. Hassane Zarour Professor of Medicine, Immunology and Dermatology University of Pittsburgh R&D Day June 7, 2022
Slide 65: Immune Checkpoint Inhibitors are among the most potent solid tumor therapies
Immune Checkpoint Inhibitors (ICI) have become one of the most potent therapy of solid tumors Head& Neck Melanoma Cancer • In the US, 70% of melanoma patients will receive an ICI. Lung Cancer Breast Cancer (NSCLC, SCLC) • ICI are first-line treatments in HCC (Liver) metastatic melanoma, NSCLC, RCC,
Slide 66: Baseline gut microbiome influences response rate to ICI
The baseline gut microbiome influences response rate to ICI • Multiple studies show an impact of the gut microbiome composition on ICI response rate in metastatic melanoma (and other solid tumors indications: lung cancer, colorectal, bladder…) • Responders and non-responders show different microbiom
Slide 67: Baseline fecal microbiome predicts PFS in melanoma patients
Baseline fecal microbiome of anti- PD-1-treated melanoma patients predicts PFS at 9-10 months Maximal impact of (baseline) gut microbiota No Progression is observed at 10 months, which is when progression Beneficial and detrimental taxa linked with patients typically escape therapy response to anti-
Slide 68: Baseline gut microbiome influences treatment-related adverse events
The baseline gut microbiome also influences treatment- related adverse events Patients with treatment-related Sensitivity to irAE and related adverse-events (irAE) have a distinct survival are impacted by specific gut microbiome profile microbiota species • Baseline microbiome composition is irAE re
Slide 69: Host fecal transcriptome shows pro-inflammatory gene signature
Host (human) fecal transcriptome shows in progressor patients a pro-inflammatory gene signature Microbiome intervention may Dendritic Cells Epithelial cells overcome the mechanisms driving a pro- Macrophages T cells Neutrophils Basophils inflammatory gene signature in the gut. Gene Set Enrichment
Slide 70: Microbiome intervention (FMT) may help restore response to ICI
Microbiome intervention (FMT) may help restore or induce response to Immune Checkpoint Inhibitors 2 recent proof-of-concept studies with FMT: • Davar et al (Science 2021) Responders’ microbiota transferred to Non- Responders Single FMT before ICI treatment 6/15 NR R, with lasting response • S
Slide 71: Microbiome therapies open a new horizon for patients receiving ICIs
Microbiome therapies open a new horizon to improve outcomes for patients receiving ICIs • In cancer patients with solid tumors, the gut microbiome composition modulates both clinical responses and immune-related adverse events to ICIs -> Microbiome interventions can be used in the clinic to : • Impr
Slide 72: PICASSO: Proof-of-concept Phase 2 trial in melanoma
Immuno- Oncology PICASSO: Proof-of-concept Phase 2 clinical trial in melanoma, sponsored by AP-HP Emilie Plantamura Head of clinical development R&D Day June 7, 2022
Slide 73: MaaT013 is designed to maximize richness
Immuno- Oncology MaaT013 is designed to maximize richness and contains specific bacterial strains that have been identified to improve ICI response Higher microbiome richness better response rate to ICI in patients with metastatic melanoma MaaT013 Gopalakrishnan et al, Science 2018 R&D Day June 7,
Slide 74: Introducing the PICASSO trial in metastatic melanoma
MaaT013 Melanoma Introducing the PICASSO trial: evaluating MaaT013 in Sponsored by patients with metastatic melanoma receiving ICIs Multi-center, Randomized, 60 patients First patient French study, placebo- treated in sponsored controlled April 2022 by AP-HP study Key study endpoints after 23 weeks
Slide 75: PICASSO: Assessing tolerance and clinical benefit of MaaT013
MaaT013 Melanoma PICASSO: Assessing tolerance and clinical benefit of MaaT013 Sponsored by in patients with metastatic melanoma naïve for ICI Screening Double-blind period: MaaT013 or placebo phase MaaT013 N=60 Placebo Every 3 weeks Every 4 weeks (prior to ipilimumab and (prior to nivolumab) nivolum
Slide 76: MaaT Pharma's dual approach in immuno-oncology
Immuno- Oncology MaaT Pharma’s dual approach in immuno-oncology • PICASSO is a proof-of-concept, exploratory trial allowing to better understand the impact of MaaT013’s bacterial richness and diversity on response to Immune Checkpoint Inhibitors, developed in partnership with AP-HP, Institut Gustave
Slide 77: MaaT Pharma's strategy to leverage the microbiome potential
MaaT Pharma’s strategy to leverage the microbiome potential to improve cancer therapies Carole Schwintner Chief Technology Officer Marianne Robin Head of R&D R&D Day June 7, 2022
Slide 78: MET platform has generated a diverse line of product candidates
MaaT Pharma’s Microbiome Ecosystem Therapy (MET) platform has generated a diverse line of product candidates Microbiome Ecosystem cGMP Therapies (MET) Platform Native Co-fermented MaaT013 MaaT033 MaaT03X Indication-specific designed High diversity ecosystem (from clinical data) Full ecosystem
Slide 79: Technological Bricks: foundations for a versatile products platform
Platform Technological Bricks: foundations for a versatile products platform MaaT033 MaaT013 Collect Deliver Characterize Pool & Freeze & Design Ferment MaaT03X-1 MaaT03X-2 MaaT03X-3 … R&D Day June 7, 2022 81
Slide 80: Safety first: Stringent vetting and testing of healthy donors
Platform Safety first: Collect Stringent vetting and testing of healthy donors Candidates VETTING Highly stringent vetting and >45 biological Healthy donors testing procedures validated by parameters tested • Standard richness multiple regulatory agencies on individual • High variability donor, ra
Slide 81: Proprietary process preserves microbiota key attributes
Platform Profile and activity matter: Pool & Proprietary process preserves microbiota key attributes Freeze Richness in OTUs Pooled material Superior richness Maximizes ButycoreTM Patented Standardized diluent MaaT013 Characteristics and high biological activity preserved in Class I frozen p
Slide 82: Oral formulation for targeted ileo-colonic delivery
Platform Optimize host/microbiome interaction: Deliver Oral formulation for targeted ileo-colonic delivery Bacterial Taxonomy Similarity preserved across all modalities 120% Pooled Oral formulation opens new material 100% indications Identity1 80% Targeted ileo-colic delivery aims to maximize 60
Slide 83: gutprint, the engine of our MET drug discovery platform
Platform gutprint®, the engine at the heart of our MET drug discovery Characterize platform & design gutPrint® synergizes clinical, product and research data to develop innovative and personalized microbiome therapy, to improve patient survival in life-threatening diseases. Predict Collect data Char
Slide 84: gutPrint integrates all available data to generate knowledge
Platform gutPrint® integrates all available data to generate knowledge Collect Clinical studies / Proprietary databases / Literature /Collaborations… Host parameters Gut microbiome Product parameters (Omics, Clinical, parameters (Omics, product immune…) (Omics, indexes, …) characteristics…) AI Chara
Slide 85: gutPrint provides critical data for drug development and manufacturing
Platform gutPrint® provides critical data for drug development and manufacturing Characterize • Proprietary tools for microbiota analysis: • All living microorganisms (bacteria, archaea, fungi…) Taxonomy, diversity, metabolism, strain detection, biomarker identification, … • Validated tools for cG
Slide 86: AI-based algorithms enable in silico indication-specific product design
Platform AI-based algorithms enable in silico indication-specific product design Design Clinical & Literature Donors Data Host and microbiome parameters Characterization AI learning of target profile Drug Design Validation (in vitro/ in vivo/clinical) R&D Day June 7, 2022 88
Slide 87: MaaT03X: Modulate the gut microbiome to improve ICI response
Platform MaaT03X: Modulate the gut microbiome to improve response rate to Immune Checkpoint Inhibitors treatment in solid tumors Ferment R&D Day June 7, 2022 89
Slide 88: A groundbreaking co-fermentation technology
Platform A groundbreaking co-fermentation technology Ferment Original microbial ecosystem cultures Targeted profile maintained through fermentation • Supportive ecosystem AND Species Species enrichment depletion • Indication-specific key functions Donor-independent and highly scalable Lower co
Slide 89: Co-fermentation maintains full supportive ecosystem
Platform Co-fermentation process maintains full supportive ecosystem and AI-selected key functionalities Ferment Full supportive ecosystem maintained in over 15 microbiota profiles tested so far, with excellent reproducibility 80-83% Taxonomic profile, viability and key indication-specific funct
Slide 90: Building Europe's largest specialized cGMP manufacturing facility for MET
Platform Collect Deliver What’s next: building Europe’s largest specialized cGMP manufacturing facility for MET Pool & Freeze Characterize & Design Ferment We are building a dedicated 1,500 square meter site (which could be doubled). This plant is designed to support commercial manufacturing of MaaT
Slide 91: Expected newsflow & ending remarks
Expected newsflow & ending remarks Hervé Affagard CEO R&D Day June 7, 2022
Slide 92: Looking ahead
Looking ahead Clinical program Next step & timeline MaaT013 (pooled enema) Intermediate review H1 2023 Onco-hematology FDA & EMA Orphan Drug Designation ORR H2 2023 MaaT033 (pooled capsule) Launch of Phase 2/3 Q4 2022 Post allo HSCT OR-ALLO (pivotal) MaaT013 (pooled enema) H1 2023 Immuno-oncology In
Slide 93: Thank you
THANK YOU Investors relations Hervé Affagard, CEO MaaT Pharma Sian Crouzet, COO/ CFO Email: invest@maat-pharma.com Phone: +33 4 28 29 14 00 R&D Day June 7, 2022 96